Working together

EMCDDA and Europol

EU Drug Markets Report

The latest EU Drug Markets Report, from the EMCDDA and Europol (April 2016), provides a unique insight into the operations of illicit drug markets in the EU and assesses their ramifications for society. The report reviews the markets for cannabis, heroin, cocaine, amphetamine, methamphetamine, MDMA and new psychoactive substances and presents concrete action points to inform policy development at EU and national level. The extensive 188-page In-depth Analysis (EN), covers trends along the supply chain from production and trafficking to marketing, distribution and consumption. It is accompanied by a Strategic Overview (ES, DE, EN, FR, PT), providing a summary of key findings as well as additional supporting material. These products combine the EMCDDA’s drug monitoring and analytical capacity with Europol’s operational intelligence on trends in organised crime.

Markets report cover

EMCDDA and Eurojust

New psychoactive substances in Europe: legislation and prosecution

The first joint publication from the EMCDDA and Eurojust — the EU’s judicial cooperation unit — focuses on New psychoactive substances in Europe: legislation and prosecution — current challenges and solutions (November 2016). The rapid evolution of the European market for new psychoactive substances has challenged national authorities to find suitable and efficient responses to the public health and judicial problems caused by these substances. This publication examines different control mechanisms and their implications

nps in europe cover
We contribute to a safer and fairer Europe
We support the free movement of people, while ensuring security and safe EU borders
We safeguard security and justice for EU citizens and promote peace within and beyond the EU
We promote gender equality and protect fundamental rights and freedoms